Version 1
: Received: 4 June 2024 / Approved: 4 June 2024 / Online: 5 June 2024 (15:20:37 CEST)
How to cite:
Mangiardi, M.; PEZZELLA, F. R.; CRUCIANI, A.; ALESSIANI, M.; ANTICOLI, S. Evaluating the Safety and Efficacy of Lacosamide Combined with NOACs in Post-Stroke Epilepsy and Atrial Fibrillation: A Prospective Longitudinal Study. Preprints2024, 2024060245. https://doi.org/10.20944/preprints202406.0245.v1
Mangiardi, M.; PEZZELLA, F. R.; CRUCIANI, A.; ALESSIANI, M.; ANTICOLI, S. Evaluating the Safety and Efficacy of Lacosamide Combined with NOACs in Post-Stroke Epilepsy and Atrial Fibrillation: A Prospective Longitudinal Study. Preprints 2024, 2024060245. https://doi.org/10.20944/preprints202406.0245.v1
Mangiardi, M.; PEZZELLA, F. R.; CRUCIANI, A.; ALESSIANI, M.; ANTICOLI, S. Evaluating the Safety and Efficacy of Lacosamide Combined with NOACs in Post-Stroke Epilepsy and Atrial Fibrillation: A Prospective Longitudinal Study. Preprints2024, 2024060245. https://doi.org/10.20944/preprints202406.0245.v1
APA Style
Mangiardi, M., PEZZELLA, F. R., CRUCIANI, A., ALESSIANI, M., & ANTICOLI, S. (2024). Evaluating the Safety and Efficacy of Lacosamide Combined with NOACs in Post-Stroke Epilepsy and Atrial Fibrillation: A Prospective Longitudinal Study. Preprints. https://doi.org/10.20944/preprints202406.0245.v1
Chicago/Turabian Style
Mangiardi, M., MICHELE ALESSIANI and SABRINA ANTICOLI. 2024 "Evaluating the Safety and Efficacy of Lacosamide Combined with NOACs in Post-Stroke Epilepsy and Atrial Fibrillation: A Prospective Longitudinal Study" Preprints. https://doi.org/10.20944/preprints202406.0245.v1
Abstract
Background and Aims: Stroke is a leading cause of seizures and epilepsy in adults, but current guidelines lack strong recommendations for treating post-stroke seizures (PSE). This study aims to demonstrate the safety and efficacy of lacosamide combined with non-vitamin K antagonist oral anticoagulants (NOACs) in patients with PSE and atrial fibrillation (AF).
Methods: In this prospective longitudinal study, 53 patients with PSE and AF, admitted from 2022 to 2023, received NOACs for AF management and lacosamide for seizure control. A control group of 53 patients with cardioembolic stroke, receiving NOACs, was matched by age, sex, and NIHSS scores to ensure comparability.
Results: Over 24 months, 16 patients in the study group and 15 in the control group experienced new embolic events, with no significant difference between groups. Seizure control improved significantly in the study group, with reduced frequency and severity. No severe adverse effects from lacosamide were observed.
Conclusions: The combination of NOACs and lacosamide is a safe and effective treatment for patients with AF and PSE, not increasing the risk of recurrent ischemic or hemorrhagic events. Further studies with larger sample sizes and longer follow-ups are needed to confirm these findings and optimize treatment protocols.
Medicine and Pharmacology, Neuroscience and Neurology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
,
